Zafgen Inc (ZFGN.OQ)
* Zafgen appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to continue as president, appointed chief scientific officer
* Zafgen initiates Phase 2 clinical trial for ZGN-1061 in patients with Type 2 diabetes Source text for Eikon: Further company coverage:
* Zafgen Inc files for a potential mixed shelf offering of up to $150 million - SEC filing Source text: (http://bit.ly/2vkwJqL) Further company coverage:
* Q2 earnings per share view $-0.52 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:
BRIEF-Zafgen preclinical abstract will present results for zgn-1061 on glycemic control, weight loss and safety profile
* Zafgen to present two late-breaking abstracts for zgn-1061 at the american diabetes association 77th scientific sessions
- Can Rhythm Pharmaceuticals Succeed Where Others Have Failed?
- Your Daily Pharma Scoop: AZN's Imfinzi SBLA; Ablynx U.S. IPO; Is Teva A Buy?
- Zafgen (ZFGN) Presents At Ladenburg Thalmann 2017 Healthcare Conference - Slideshow
- Zafgen, Inc. 2017 Q2 - Results - Earnings Call Slides
- Zafgen's (ZFGN) CEO Tom Hughes on Q2 2017 Results - Earnings Call Transcript
- Daily Insider Ratings Round Up 7/12/17: AZZ, CNBKA, IMDZ, MCC